By Casey Miller
Health & Science Correspondent
HOUSTON, TX — For nearly three years, the folder labeled “Scan Results” in Sarah Jenkins’ digital patient portal was a source of paralyzing dread. Since her 2023 diagnosis of Stage 4 metastatic breast cancer, the reports had been a repetitive litany of “progression,” “lesions,” and “persistence.”
But last Tuesday, at 10:14 a.m., the language changed. The latest radiologic report from her oncology team contained four words that Sarah, her family, and even some of her doctors thought they might never see:Â “No Evidence of Disease” (NED).
In the world of advanced oncology, “Stage 4” is a label often synonymous with “terminal.” It means the cancer has traveled from its origin to distant organs—in Sarah’s case, her lungs and bones. While modern medicine has made strides in extending life for patients with metastatic disease, a total clearance of detectable cancer is a rare and celebrated milestone.
The “unreachable” goal
Sarah’s journey began with a persistent cough that she originally dismissed as a lingering seasonal allergy. By the time she sought a specialist, the cancer had already migrated. The initial prognosis was somber: the goal was management, not a cure.
“When you hear ‘Stage 4,’ the room goes quiet,” Sarah recalled from her home, where she was recently celebrated by neighbors with a surprise ‘Pink Ribbon’ parade. “You stop planning for five years from now and start planning for next month. You learn to live in 21-day cycles of chemotherapy and prayer.”
For 18 months, Sarah underwent a grueling regimen of traditional radiation and systemic infusions. While the treatments kept the disease from spreading further, they took a heavy toll on her physical strength. By early 2025, her medical team at the MD Anderson Cancer Center decided to pivot, enrolling her in a cutting-edge clinical trial involving targeted immunotherapy.
A breakthrough in biology
The treatment, a combination of a newly approved “smart drug” and an experimental vaccine tailored to her tumor’s specific genetic markers, was designed to “train” Sarah’s own immune system to recognize and attack the cancer cells that traditional chemo had missed.
The results weren’t immediate. For the first six months, the scans showed “stable disease”—medical shorthand for “it isn’t getting worse, but it isn’t getting better.” However, by the nine-month mark, the shadows on her lung scans began to fade. By one year, the bone lesions showed signs of significant healing.
“What we are seeing with Sarah is the pinnacle of personalized medicine,” said Dr. Aris Thorne, an oncologist involved in the trial. “We aren’t just carpet-bombing the body with chemicals anymore. We are providing the immune system with a high-definition map of the enemy. In Sarah’s case, her body took that map and ran with it.”
The weight of “NED”
The term “No Evidence of Disease” is distinct from “cured.” In the medical community, it means that using current imaging technology—PET scans, MRIs, and blood markers—no active cancer can be found. For patients like Sarah, it is a hard-won truce that allows them to reclaim a life that was once on indefinite hold.
“It feels like I’ve been holding my breath for three years and I finally just exhaled,” Sarah said, clutching a framed photo of her seven-year-old daughter. “I went from planning my legacy to planning a camping trip for this summer. The difference between those two things is everything.”
A ripple of hope
Sarah’s story has quickly become a beacon for the online community of “Metavivors”—men and women living with metastatic breast cancer. Her social media posts, once filled with updates on side effects and hospital gowns, are now flooded with comments from patients across the country asking for her protocol and sharing their own stories of resilience.
While Dr. Thorne cautions that every patient’s biology is unique and not everyone responds to immunotherapy in the same way, Sarah’s case provides vital data for researchers. “Every ‘NED’ result in a Stage 4 patient is a puzzle piece,” Thorne explained. “It tells us what is possible. It moves the goalposts for everyone else.”
As for Sarah, she isn’t spending too much time analyzing the science. She is busy doing the things she once feared she’d never do again: grocery shopping without a mask, walking her dog in the park, and looking at the 2027 calendar with a pen in her hand.
“I don’t know what tomorrow holds,” she said with a smile. “But for today, the scans are clear. And today is a very good day.”
